| Literature DB >> 35572483 |
Hiroshi Takeyama1, Shingo Noura1, Yozo Suzuki1, Kazuki Odagiri1, Yoshitomo Yanagimoto1, Masafumi Yamashita1, Junzo Shimizu1, Tomono Kawase1, Hiroshi Imamura1, Takashi Iwazawa1, Naohiro Tomita1, Keizo Dono1.
Abstract
Objectives: In elderly colorectal cancer (CRC) patients, preoperative surgical indications can be controversial in some cases depending on the patient's physical condition. In comparison with younger patients, both cancer-specific survival (CSS) and non-CCS (NCSS) have an impact on the prognosis and both CSS and NCSS should be considered in the preoperative assessment. We aimed to investigate the impact of body mass index (BMI) on CSS and NCSS in Japanese elderly CRC patients.Entities:
Keywords: body mass index; colorectal cancer; elderly; non-cancer-specific survival; octogenarian
Year: 2022 PMID: 35572483 PMCID: PMC9045859 DOI: 10.23922/jarc.2021-056
Source DB: PubMed Journal: J Anus Rectum Colon ISSN: 2432-3853
Figure 1.Flow diagram of patient disposition. The following variables were used for propensity score matching between the higher body mass indexes (BMI) and lower BMI groups: age, sex, location of lesion, serum carcinoembryonic antigen level, histological type, surgical approach, American Society of Anesthesiologists Performance Status, adjuvant chemotherapy, postoperative complications, and stage.
Patient Baseline Data before and after Propensity Score Matching.
| Characteristic | Overall cohort | After matching | ||||||
|---|---|---|---|---|---|---|---|---|
| Higher BMI
| Lower BMI
|
| Higher BMI
| Lower BMI
|
| |||
| BMI, mean (IQR) | 24.5 (23.8-25.5) | 20.1 (18.4-21.5) | <.001*** | 24.5 (23.8-25.5) | 20.1 (18.4-21.9) | <.001*** | ||
| Age, mean (IQR) | 83 (81-85) | 84 (81-87) | .017* | 83 (81-85) | 82 (81-85) | .847 | ||
| Sex | Male, n (%) | 64 (49.6) | 157 (45.9) | .535 | 60 (48.8) | 55 (44.7) | .609 | |
| Female, n (%) | 65 (50.4) | 185 (54.1) | 63 (51.2) | 68 (55.3) | ||||
| Approach | Laparoscopic | 66 (51.2) | 114 (33.3) | <.001*** | 61 (49.6) | 59 (48.0) | .899 | |
| Open | 63 (48.8) | 228 (66.7) | 62 (50.4) | 64 (52.0) | ||||
| CEA, median (IQR) | 4.5 (2.5-7.6) | 4.4 (2.6-9.2) | .858 | 4.3 (2.5-7.6) | 3.9 (2.4-6.4) | .329 | ||
| ASA | 1, n (%) | 13 (10.1) | 45 (13.2) | <.001*** | 13 (10.6) | 13 (10.6) | 1.000 | |
| 2, n (%) | 94 (72.9) | 179 (52.3) | 89 (72.4) | 89 (72.4) | ||||
| 3, n (%) | 21 (16.3) | 111 (32.5) | 20 (16.3) | 20 (16.3) | ||||
| 4, n (%) | 1 (0.8) | 6 (1.8) | 1 (0.8) | 1 (0.8) | ||||
| 5, n (%) | 0 | 1 (0.3) | 0 | 0 | ||||
| Tumor Location | Right-sided colon, n (%) | 60 (46.5) | 171 (50.0) | .789 | 57 (46.3) | 57 (46.3) | 1.000 | |
| Left-sided colon, n (%) | 35 (27.1) | 87 (25.4) | 34 (27.6) | 34 (27.6) | ||||
| Rectum, n (%) | 34 (26.4) | 84 (24.6) | 32 (26.0) | 32 (26.0) | ||||
| Histological type | Tub | 108 (83.7) | 296 (86.5) | .460 | 104 (85.5) | 100 (81.3) | .612 | |
| Non-tub | 21 (16.3) | 46 (13.5) | 19 (15.5) | 23 (18.7) | ||||
| UICC 8th Stage | I, n (%) | 28 (21.7) | 66 (19.3) | .429 | 27 (22.0) | 27 (22.0) | .811 | |
| IIA, n (%) | 57 (44.2) | 127 (37.1) | 53 (43.1) | 48 (39.0) | ||||
| IIB, n (%) | 4 (3.1) | 21 (6.1) | 4 (3.3) | 5 (4.1) | ||||
| IIC, n (%) | 1 (0.8) | 10 (2.9) | 1 (0.8) | 2 (1.6) | ||||
| IIIA, n (%) | 26 (20.2) | 78 (22.8) | 25 (20.3) | 26 (21.1) | ||||
| IIIB, n (%) | 8 (6.2) | 20 (5.9) | 8 (6.5) | 5 (4.1) | ||||
| IIIC, n (%) | 5 (3.9) | 20 (5.9) | 5 (4.1) | 10 (8.1) | ||||
| Adjuvant therapy | Present, n (%) | 6 (4.7) | 19 (5.6) | .820 | 5 (4.1) | 6 (4.9) | 1.000 | |
| Absent, n (%) | 123 (95.3) | 323 (94.4) | 118 (95.9) | 119 (95.1) | ||||
| Postoperative complication | Absent, n (%) | 86 (66.7) | 251 (73.4) | .169 | 84 (68.3) | 86 (69.9) | .890 | |
| Present, n (%) | 43 (33.3) | 91 (26.6) | 39 (31.7) | 37 (30.1) | ||||
BMI, body mass index; IQR, interquartile range; CEA, carcinoembryonic antigen; ASA, American Society of Anesthesiologists; Tub, tubular adenocarcinoma.
* P-value <.05, ** P-value <.01, *** P-value <.001
Figure 2.Kaplan–Meier curves of the higher body mass index (BMI) and lower BMI groups for (a) cancer-specific survival (CSS), (b) non-cancer-specific survival (NCSS), and (c) overall survival (OS) after propensity score matching. Using a log-rank test, significant differences were identified between the higher BMI and lower BMI groups’ NCSS and OS (P < .001 and < .001, respectively).
Univariate and Multivariate Cox Regression Hazards Analyses of Risk Factors for Overall Survival.
| Factors | Univariate | Multivariate | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CSS | NCSS | OS | CSS | NCSS | OS | ||||||||||||
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| ||||||
| Higher BMI (≥23) | Ref. | .027* | Ref. | <.001*** | Ref. | <.001*** | Ref. | .027* | Ref. | <.001*** | Ref. | <.001*** | |||||
| Lower BMI (<23) | 1.862
| 2.588
| 2.279
| 1.867
| 2.331
| 2.230
| |||||||||||
| Female | Ref. | .421 | Ref. | .008** | Ref. | .009** | Ref. | .005** | Ref. | .017* | |||||||
| Male | 1.209
| 1.606
| 1.449
| 1.651
| 1.408
| ||||||||||||
| CEA levels ≤5 ng/ml | Ref. | .056 | Ref. | .705 | Ref. | .392 | |||||||||||
| >5 ng/ml | 1.580
| 0.946
| 1.133
| ||||||||||||||
| ASA 1-2 | Ref. | .262 | Ref. | <.001*** | Ref. | <.001*** | Ref. | .021* | Ref. | .017* | |||||||
| 3-5 | 1.330
| 1.971
| 1.718
| 1.563
| 1.453
| ||||||||||||
| Colon | Ref. | .382 | Ref. | .360 | Ref. | .209 | |||||||||||
| Rectum | 1.259
| 1.201
| 1.222
| ||||||||||||||
| Tub | Ref. | .265 | Ref. | .287 | Ref. | .126 | |||||||||||
| Non-tub | 1.445
| 1.334
| 1.378
| ||||||||||||||
| Stage I-II | Ref. | <.001*** | Ref. | .104 | Ref. | .009** | Ref. | <.001*** | Ref. | .038* | |||||||
| III | 4.443
| 0.719
| 1.476
| 4.042
| 1.363
| ||||||||||||
| Approach Lap | Ref. | .432 | Ref. | .018* | Ref. | .021* | Ref. | .313 | Ref. | .637 | |||||||
| Open | 1.219
| 1.653
| 1.456
| 1.268
| 1.088
| ||||||||||||
| Adjuvant chemotherapy (+) | Ref. | .362 | Ref. | <.001*** | Ref. | .062 | Ref. | <.001*** | |||||||||
| (-) | 1.465
| 5.749
| 1.795
| 6.172
| |||||||||||||
| Post-operative complication (-) | Ref. | .002** | Ref. | .097 | Ref. | .001** | Ref. | .005** | Ref. | <.001*** | |||||||
| (+) | 2.215
| 1.406
| 1.676
| 2.370
| 1.717
| ||||||||||||
CSS, cancer specific survival; NCSS, non cancer specific survival; OS, overall survival; CI, confidence interval; BMI, body mass index; CEA, carcinoembryonic antigen; ASA, American Society of Anethesiologists; Tub, tubular adenocarcinoma; Lap, laparoscopic
* P-value <.05, ** P-value <.01, *** P-value <.001
Causes of Death after Surgery before and after Propensity Score Matching.
| Overall cohort | After matching | ||||||
|---|---|---|---|---|---|---|---|
| Higher BMI
| Lower BMI
|
| Higher BMI
| Lower BMI
|
| ||
| Total number of deaths, n (%) | 33 (25.6) | 166 (48.5) | <.001*** | 32 (26.0) | 55 (44.7) | .003** | |
| Death from primary cancer | 14 | 58 | .433 | 14 | 21 | .655 | |
| Death from other diseases | 19 | 108 | 18 | 34 | |||
| Other cancer death | 7 | 25 | N.A. | 7 | 8 | N.A. | |
| Respiratory disease | 0 | 14 | 0 | 8 | |||
| Heart disease | 1 | 10 | 1 | 2 | |||
| Gastroenterological disease | 0 | 6 | 0 | 1 | |||
| Renal and urinary disease | 0 | 5 | 0 | 0 | |||
| Brain-related disease | 1 | 3 | 0 | 1 | |||
| Sudden death | 1 | 3 | 1 | 0 | |||
| Aortic rupture | 1 | 1 | 1 | 1 | |||
| Senile decay | 0 | 2 | 0 | 0 | |||
| Unknown other than cancer | 8 | 39 | 8 | 13 | |||
| Stage I (n = 94) | 28 | 66 | 27 | 27 | |||
| Total number of deaths | 6 | 27 | .098 | 6 | 12 | .148 | |
| Death from primary disease | 0 | 1 | 1.000 | 0 | 1 | 1.000 | |
| Death from other disease | 6 | 26 | 6 | 11 | |||
| Stage II (n = 220) | 62 | 158 | 58 | 55 | |||
| Total number of death | 15 | 73 | .004** | 14 | 23 | .070 | |
| Death from primary disease | 5 | 19 | .542 | 5 | 6 | .713 | |
| Death from other disease | 10 | 54 | 9 | 17 | |||
| Stage III (n = 157) | 39 | 118 | 38 | 41 | |||
| Total number of deaths | 12 | 66 | .009** | 12 | 20 | .169 | |
| Death from primary disease | 9 | 38 | .344 | 9 | 14 | 1.000 | |
| Death from other disease | 3 | 28 | 3 | 6 | |||
BMI, body mass index; N.A., not analyzed.
* P-value <.05, ** P-value <.01, *** P-value <.001